Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Terminated Phase 2 Interventional Results available

Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia

NCT03564678
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Hyperbilirubinemia
Interventions
Levocarnitine, Vitamin B Complex
Dietary Supplement · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 16, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

NCT03066206
View directory record Official record
Conditions
EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Poziotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

NCT01786343
View directory record Official record
Conditions
Leukemia
Interventions
Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells

NCT01362452
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
T-Cell Infusion, Cord Blood Infusion
Genetic · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 16, 2026, 9:59 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work

NCT05038384
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 16, 2026, 9:59 AM EDT
Terminated No phase listed Observational

Bone Loss in Melanoma Survivors Receiving Immunotherapy

NCT04516122
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

NCT00656448
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions
Procrit
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 16, 2026, 9:59 AM EDT
Terminated Not applicable Interventional Results available

Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases

NCT02715856
View directory record Official record
Conditions
Bone Metastases, Cancer Survivor, Metastatic Malignant Neoplasm in the Bone
Interventions
Monitoring Device, Physical Activity Measurement, Quality-of-Life Assessment, Questionnaire Administration, Standard Follow-Up Care, Survey Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

NCT01237951
View directory record Official record
Conditions
Myeloma
Interventions
Palifermin, Dexamethasone, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Not applicable Interventional

Acupuncture for Treatment of Uncontrolled Pain: A Feasibility Study

NCT00487331
View directory record Official record
Conditions
Solid Tumors, Pain
Interventions
Acupuncture, Survey
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

NCT02593175
View directory record Official record
Conditions
Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Paclitaxel, Panitumumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 16, 2026, 9:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

NCT03735875
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia
Interventions
Quizartinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib Malate in Refractory Germ Cell Tumors

NCT00912912
View directory record Official record
Conditions
Genitourinary Disease
Interventions
Sunitinib Malate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 16, 2026, 9:59 AM EDT
Enrolling by invitation No phase listed Observational

Optimal Duration of Spinal Cord Stimulation Trial Procedure: Length and Diagnostic Accuracy

NCT07016581
View directory record Official record
Conditions
Chronic Pain
Interventions
Daily survey
Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 16, 2026, 9:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Increasing Access to Smoking Cessation and Smoke Free Home Services for Low-Income Pregnant Women in Northeast Texas

NCT05051345
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Informational Intervention, Media Intervention, Questionnaire Administration, Smoking Cessation Intervention, Survey Administration, Telephone-Based Intervention, Tobacco Cessation Counseling
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 16, 2026, 9:59 AM EDT
Recruiting Not applicable Interventional

Telephone Support in Advanced Gastrointestinal Cancer

NCT06532877
View directory record Official record
Conditions
Gastrointestinal Neoplasm Malignant, Caregiver Burden
Interventions
Acceptance and Commitment Therapy, Education/Support
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 16, 2026, 9:59 AM EDT
Active, not recruiting Not applicable Interventional

Multi-site Feasibility and Acceptability of a Faith-based Mind-body Intervention for Black Adults

NCT05791981
View directory record Official record
Conditions
Psychosocial, Mind-body
Interventions
Harmony & Health Intervention, Attention Control, Fitbit
Behavioral · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 16, 2026, 9:59 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

NCT05681039
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Interventions
Tiragolumab, Atezolizumab, Standard of Care, Questionnaires, Cisplatin, Carboplatin
Drug · Behavioral · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 16, 2026, 9:59 AM EDT
Active, not recruiting Not applicable Interventional

PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer

NCT03965481
View directory record Official record
Conditions
Malignant Ovarian Neoplasm, Ovarian Carcinoma
Interventions
Dynamic Enhanced CT, Magnetic Resonance Imaging, Positron Emission Tomography
Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Not applicable Interventional

DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis

NCT03685539
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Dual-Energy Computed Tomography
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 16, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

NCT05036681
View directory record Official record
Conditions
Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
Interventions
Futibatinib, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Respiratory Syncytial Virus - RSV Protocol

NCT01502072
View directory record Official record
Conditions
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 16, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

NCT00428545
View directory record Official record
Conditions
Advanced Malignancy, Lymphoma, Myeloma, Solid Tumors
Interventions
Bevacizumab, Bortezomib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 16, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

NCT03121534
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Richter's Transformation
Interventions
Blinatumomab, Dexamethasone, Ibrutinib, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 16, 2026, 9:59 AM EDT